Navigation Links
Patent awarded for method to dampen immune response
Date:1/18/2011

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants. This therapeutic approach has the potential advantage of inactivating B cells instead of killing them as current treatments do. Therefore, this potential therapy could be more rapidly adjusted in response to the changing needs of patients.

B cells are a crucial part of the adaptive immune response, responsible for making antibodies that can neutralize and destroy pathogens. Several diseases, however, are associated with malfunction of B cells. For example, B cells can turn cancerous in diseases such as lymphoma and leukemia. In autoimmune diseases, such as rheumatoid arthritis or lupus, B cells turn against their own bodies and attack their tissues. B cells can also attack transplanted organs, which they recognize as foreign and potentially harmful.

The recently issued patent describes a method to inactivate B cells by disassembling their B-cell receptors. B cells begin producing antibodies after their B-cell receptors encounter foreign protein fragments, known as antigens. The B-cell receptor contains two distinct subunits; a receptor, which engages antigens, and a transducer, which transmits an activating signal to the interior of the cell.

About a decade ago, Dr. Cambier's laboratory, discovered that the two subunits could be separated, which disables the B cell's ability to recognize antigens and produce antibodies. In 2003, National Jewish Health received a patent (#6,503,509) for this method of B -cell desensitization. The most recent patent (#7,825,224) related to this technology claims the use of antibodies that bind to the transducer subunit of the receptor to inactivate the B cell.

Dr. Cambier's laboratory has recently developed several antibodies against one of the transducer elements, CD79, that have already yielded promising results.

"In contrast to current therapies for B-cell diseases, this method does not kill B cells, it merely inactivates them," said Dr. Cambier. "That could potentially allow for greater flexibility in using a therapy that is developed with this technology. Instead of the months to years it sometimes takes for the effects of current therapy to wane, our method could be reversed within days."

Dr. Cambier has recently received research funding from the State of Colorado and National Jewish Health through the Bioscience Discovery Evaluation Grant Program to further develop this promising technology.

"This research funding underlines our commitment to promote the translation of our scientists' research findings into therapeutic or diagnostic products that can ultimately help patients worldwide," said Emmanuel Hilaire, PhD, Manager of the Technology Transfer Office at National Jewish Health. "National Jewish is currently exploring various commercialization venues for its licensing, including the creation of a start-up company in Colorado."


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related medicine news :

1. National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria
2. National Jewish Health receives patent for liposome-based vaccine
3. K-State receives patent for noncontroversial source of stem cells
4. 15 new US patents awarded this past year to NJIT researchers
5. UR discovers new way to boost vaccines, seeks patent
6. Brookhaven Lab and BioSET Inc. patent improved growth factor technology
7. USF receives patent for technology to improve treatment for neurodegenerative diseases
8. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
9. Greenway Awarded U.S. Patent For EHR Functionality and Workflow
10. Volumetrics Medical Imaging, LLC and Medison Co., Ltd. Announce Technology License and Settlement of Patent Litigation
11. Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too.....
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: